Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results

Artiva Biotherapeutics (NASDAQ:ARTV) announced its quarterly earnings data on Tuesday. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.03, FiscalAI reports.

Artiva Biotherapeutics Stock Up 17.3%

Shares of NASDAQ:ARTV opened at $7.13 on Thursday. The firm has a fifty day moving average of $4.68 and a two-hundred day moving average of $3.92. The firm has a market capitalization of $175.04 million, a P/E ratio of -2.08 and a beta of 2.16. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $7.75.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ARTV. HC Wainwright boosted their target price on Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, January 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of ARTV. Prelude Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $41,000. Bank of America Corp DE lifted its stake in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at $53,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics during the second quarter worth $58,000. Finally, Jane Street Group LLC acquired a new position in Artiva Biotherapeutics during the second quarter worth $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.